CINECA IRIS Institutional Research Information System

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma

Scagliotti, Giorgio V.
First
;
2017-01-01
2017
CLINICAL LUNG CANCER
18
5
589
593
http://www.journals.elsevier.com/clinical-lung-cancer/
Adaptive design; Antiangiogenesis; Epithelioid; First-line; VEGF; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Indoles; Induction Chemotherapy; Maintenance Chemotherapy; Male; Mesothelioma; Pemetrexed; Pleural Neoplasms; Research Design; Survival Rate; Oncology; Pulmonary and Respiratory Medicine; Cancer Research
Scagliotti, Giorgio V.*; Gaafar, Rabab; Nowak, Anna K.; Reck, Martin; Tsao, Anne S.; van Meerbeeck, Jan; Vogelzang, Nicholas J.; Nakano, Takashi; von Wangenheim, Ute; Velema, Derek; Morsli, Nassim; Popat, Sanjay
03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
LUME-M~1.PDF

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 233.16 kB
Formato Adobe PDF
  Visualizza/Apri   Richiedi una copia
233.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1680272
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact